Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD4831 in Healthy Males
NCT03136991Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mitiperstat in heart failure with preserved ejection fraction (HFpEF) (5 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, Systolic Blood pressure and 12 more. Started May 2017; status: completed.
02
Drugs
mitiperstat
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03136991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136991.